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Aim: To evaluate the long-term course of outcome indexes in patients with chronic
obstructive pulmonary disease (COPD) undergoing repeated pulmonary rehabilitation
programs (PRP).
Design: Prospective, observational study.
Setting: Pulmonary Rehabilitation Center.
Patients: Forty-eight COPD patients (M 33, age 59.678.9 years, forced expiratory volume
in 1 s (FEV1) 58716% predicted, DLCO 71717% predicted.) undergoing 5 Day-Hospital
based PRPs in a period of 7.270.8 years.
Measurements: Lung function, exercise capacity (incremental cycloergometry, test-6-
minute walking test (6MWD)), dyspnoea (Baseline-BDI and Transitional-TDI Dyspnoea Index
and Medical Research Council score—MRC), health-related quality of life (HRQL) (St.
George Respiratory Questionnaire (SGRQ), and the derived BODE index were assessed pre
and post each PRP.
Results: During follow-up, patients showed a 18722 (mean7SEM)ml/year FEV1 decline
(95%CI: 24.4 to 11.6; po0.001). Exercise tolerance and BDI remained stable over time
whereas SGRQ improved (DSGRQ total score: 9.6714%, po0.001). BODE index
significantly worsened (from 1.2771.14 to 1.9871.64; po0.001), being this change
mainly attributable to worsening in FEV1. Each PRP elicited significant improvement inElsevier Ltd. All rights reserved.
mologia, Dipartimento Cardio-Toracico, Azienda Ospedaliero-Universitaria Pisana, Via Paradisa 2,
50996786; fax: +39 050996779.
isa.toscana.it (N. Ambrosino).
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K. Foglio et al.1962exercise capacity, dyspnoea, SGRQ and BODE score. Post-PRP improvements in 6MWD, MRC
and TDI were higher after the first three than after the last two PRPs (po0.001), whereas
the greatest gain in SGRQ was observed after PRP1 and then it was lower (po0.03) but
stable in the following periods of observation.
Conclusion: Despite progressive lost in effectiveness of repeated PRP, COPD patients
undergoing those programs do not show any significant worsening in exercise tolerance,
dyspnoea and HRQL along a period of 7 years.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of death, a major medical and an increasing economic
problem.1 The disease results in a progressive worsening in
lung function, dyspnoea, exercise capacity and health-
related quality of life (HRQL).2,3 Pulmonary rehabilitation
has been well established as a means of enhancing standard
therapy to alleviate symptoms and optimise function
independent of the stage of disease.1,4 Intensive, multi-
disciplinary, outpatient pulmonary rehabilitation programs
(PRP) are an effective intervention in the short- and the
long-term: benefits including improved exercise tolerance,
symptoms, and HRQL with decrease in health care expen-
ditures.4,5 The benefits appear to decline after 6–12 months
following the formal program, benefits in HRQL being better
preserved than exercise performance,6 and may still be
identified up to 2 years after the intervention.7
Few data are available on long-time course of outcome
measures in COPD patients. Therefore, we have observed
the 7-year course of pulmonary function, symptoms,
exercise tolerance and HRQL in COPD patients undergoing
repeated PRPs.
Materials and methods
The study was conducted according to the declaration of
Helsinki. Informed consent for personal data treatment for
routinary and scientific use was obtained by every patient at
admission into our department and approved by the ethical
committee of Fondazione S. Maugeri.
Patients
The study population included all COPD patients consecu-
tively admitted for the first time to the Scientific Institute of
Gussago, Salvatore Maugeri Foundation, for Day-Hospital-
based PRP from January 1996 to June 1998. During this
period 65 COPD patients were admitted. At the end of the
observational period (June 2005) 48 patients had performed
five PRPs. Out of the 17 patients lost during the observa-
tional period, 5 patients died due to acute respiratory
failure (1 patient), lung cancer (2 patients), rupture of
abdominal aortic aneurysm (1 patient) and prostatic cancer
(1 patient); 12 further patients were lost at follow-up. Time
elapsed from PRP1 to PRP5 was 7.270.8 years, whereas the
average interval between each PRP was 1.470.5 years. The
Scientific Institute of Gussago is referral rehabilitation andchronic care centre for a large geographic area in Northern
Italy. After a first evaluation and performance of a PRP,
patients are usually followed at outpatient clinics and
repeat PRP at interval of 12–18 months according to the
logistic needs of patients and hospital. Two-year follow-up
data of some of these patients have been published
previously.6,7
Diagnosis of COPD was made in the presence of history of
smoking (410 pack-year), a post-bronchodilator forced
expiratory volume in 1 s (FEV1) o80% of predicted and a
FEV1/forced vital capacity (FVC) ratio o0.7. Patients were
retrospectively stratified according to Global Initiative for
Chronic Obstructive Lung Disease (GOLD)1 stages of severity.
At admission to PRP, all patients had stopped smoking for
2–10 years, were in stable conditions, as assessed by
absence of worsening in symptoms, stability in blood gas
values (no respiratory acidosis), and were free from
exacerbations as defined by a change in the patient’s
baseline dyspnoea, cough and/or sputum beyond day-to-day
reliability sufficient to warrant a change in management, in
the 4 weeks prior to PRP. Patients with a post-bronchodilator
(200mcg of salbutamol) change in FEV1 415% or 4200ml
were excluded from the study as well as patients with other
organ failure, cancer or inability to cooperate. All patients
received regular treatment with inhaled bronchodilators
and inhaled steroids according to current guidelines for their
disease stage. In case of exacerbation of the disease,
patients could change regular treatment or add oral
steroids; changes in regular treatment were, however,
recorded at the moment of the next follow-up visit or
admission to PRP.Pulmonary rehabilitation program
Our PRP was a Day-Hospital-based multidisciplinary 8-week
PRP which has been described elsewhere6,7 including the
optimisation of drug therapy, three 3-h sessions per week for
8–10 weeks, with: (i) supervised incremental exercise until
achieving 30min continuous cycling at 50–70% of the
maximal load achieved on an incremental cycloergometer
exercise test carried out at admission8; (ii) abdominal,
upper and lower limb muscle activities lifting progressively
increasing light weights (300–500 gm), shoulder and full arm
circling9; (iii) patient and family education; (iv) nutritional
programs and psychosocial counselling, when appropriate. A
multidisciplinary team consisting of chest physicians,
nurses, physical therapists, dietician and psychologist
offered care. If desired, patients could rest in dedicated
beds and have meals at the hospital facilities.
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as outpatients for control visits every 6 months. They were
encouraged to perform activities of daily life (ADL) but no
structured exercise programs were prescribed. Also patients
could contact the center for extra visits at any time, if
needed.
Outcome measurements
Outcome measures were assessed prior to (T1, T3, T5, T7,
T9) and at the end of each PRP (T2, T4, T6, T8, T10).
Lung function
Spirometry and lung volumes were assessed according to the
American Thoracic Society (ATS) guidelines.10 Dynamic lung
volumes were calculated by means of a mass flow sensor
(model VMax 22C Sensor Medics, Yorba Linda, CA, USA)
whereas static lung volumes were measured by means of a
constant volume body plethysmograph (model VMax 62
Sensor Medics, Yorba Linda, CA, USA). The predicted values
according to Quanjer11 were used. Arterial blood gases were
measured by means of automated analysers (840 Ciba
Corning, Medfield, MA, USA; RapidLab 865, Bayer Corpora-
tion East Walpole, MA, USA) on samples from the radial
artery while the patients in the sitting position were
breathing room air for at least 1 h. Maximal inspiratory
(MIP) and expiratory (MEP) pressures were measured at the
level of Functional Residual Capacity (FRC),12 using a
respiratory module system (Sensor Medics, Yorba Linda,
CA, USA). The predicted values according to Bruschi et al.13
were used. Diffusing capacity for carbon monoxide (DLCO)
was measured by the single-breath technique using a
dedicated module system (Sensor Medics, Yorba Linda, CA,
USA) according to ATS standards14 and utilising normal
reference values derived from those of Crapo and collea-
gues.15
Exercise capacity
Symptom limited incremental exercise tests were per-
formed on an electrically braked cycloergometer (Ergome-
tris 800S, Sensormedics, Yorba Linda, CA, USA) using the
standard 1-min incremental cycle exercise protocol as
previously described.6,7 Functional and metabolic data were
determined at rest and during exercise by means of a
computerised system (2900Z, Sensormedics, Yorba Linda,
CA, USA). At rest and at 10-W intervals, patients were asked
their perceived breathlessness and leg fatigue by pointing a
number or phrase on a 10-point modified Borg scale16 set in
large type on a sheet in front of them. Exercise capacity was
evaluated also by means of the 6-minute walking test
(6MWD) according to standard guidelines.17 All measure-
ments were performed and recorded under the supervision
of nurses not involved in the study.
Dyspnoea
Italian versions of the Medical Research Council (MRC)
scale18 and of the Baseline (BDI) and the Transitional
Dyspnoea Index (TDI)19 were used to assess chronic exertion
dyspnoea, prior to each PRP and pre–post-PRP changes in
dyspnoea, respectively.Quality of life
The HRQL was evaluated by means of a validated Italian
translation of the ‘‘St. George’s Respiratory Questionnaire’’
(SGRQ).20,21
The BODE Index, which integrates body mass index,
airflow limitation (FEV1), MRC score and 6MWD was also
calculated retrospectively.22
Exacerbations and hospitalisation
The procedure of recording exacerbations and hospitalisa-
tion has been described elsewhere.7 For the purpose of this
study, we defined exacerbations as episodes not requiring
hospitalisation but requiring a change of usual medication
and prescription of systemic steroids and/or antibiotics by
the general practitioner or the respiratory physician.
Hospital admissions were decided by the patients’ general
practitioners. The number of hospitalisations and exacerba-
tions not requiring hospitalisation in the last year (follow
back) prior to PRP-1 were recorded. These data were
obtained asking the patients at follow-up visits, from the
hospital registers, and interviewing relatives or the general
practitioner. After discharge from the PRP1, patients were
asked to keep a record of hospital admissions and exacer-
bations. Furthermore, data were collected from hospital
registers, interviewing relatives, or the general practitioner.
Finally, mortality rate was recorded at the follow-up visit.
Statistical analysis
Results are expressed as mean71 standard error of the
mean (SEM) or deviation (SD) when specified. All analyses
were performed using a specific software (SPSS release 12.0,
SPSS Inc. Chicago, USA). Differences between paired groups
of data were evaluated by T-test or Wilcoxon signed rank
test, when appropriate. Time course of variables was
evaluated by univariate analysis of variance (ANOVA) for
repeated measure options with Bonferroni’s adjustment for
normally distributed variables. Time course of non-para-
metric variables (mainly dyspnoea scores and SGRQ) were
analysed by means of Friedman’s test, followed by multiple
Wilcoxon signed ranks tests. According to the post-PRP
change in exercise performance (6MWD) and in SGRQ, the
patients were divided ex post facto into two groups:
improvers (either an increase in 6MWD by at least 54
meters23; or a reduction in SGRQ total score by at least 4%24
and non-improvers. w2 analysis was performed for evaluation
of differences in frequencies of non-parametric variables.
Coefficients of correlation were calculated using Pearson’s
and Spearman’s tests for parametric and non-parametric
variables, respectively. A p valueo0.05 or less was
considered as significant.
Results
Time course of pre-PRP outcome measures
Lung and respiratory muscle function
Functional characteristics of the patients in study at each
PRP admission are shown in Table 1. Patients were retro-
spectively classified according to GOLD1 stages I–IV taking
into account FEV1 value measured at T0. Out of 48 patients,
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Table 1 Anthropometric, demographic and functional data of all patients that completed five PRPs (48 patients).
Stage T1 T3 T5 T7 T9 ANOVA p
Sex, M/F 33/15
Age 59.678.1
Body mass index 26.974.4 2774.6 27.274.6 27.174.3 27.374.6 0.31
BODE score, total
score
1.2771.14 1.2171.22 1.471.2 1.5871.47 1.9871.64 o0.001
FVC, % predicted 79.8714.4 80.6714.7 81.1715.7 82715 81.3715.4 0.56
VC, % predicted 84715 86715 84716 84717 84715 0.30
FEV1, ml 16207560 16017555 15517541 15507576 14907559
 o0.001
FEV1, % predicted 57.7716.3 57.6716 56.4715.2 56.3716.3 54.6716.1
y 0.002
RV, % predicted 147738 145737 149738 145741 150737 0.08
TLC, % predicted 111717 111717 110717 111717 110721 0.91
MIP, % predicted 65.9716.6 65.6717.3 65.6718 66718.2 64.5718.2 0.78
MEP % predicted 68.3717 68.8717.5 68.2718.3 64.5716.9 60.1713.5 o0.001
DLCO, % predicted 70.9716.6 68.58716 70717.3 66.9716.1 63.4717.4 o0.001
PaO2, mmHg 76.378 76.978.4 75.479.1 74.678.1 74.379.7 0.034
PaCO2, mmHg 38.874.3 38.673.5 38.373.8 38.973.9 3973.9 0.59
pH 7.4070.2 7.4170.2 7.4170.2 7.4170.2 7.4170.2 0.140
Pair-wise comparison with Bonferroni’s adjustment: po0.001 versus T1.
yPair-wise comparison with Bonferroni’s adjustment: p ¼ 0.027 versus T1.
K. Foglio et al.19646 were in GOLD stage I (12.5%), 27 in stage II (56.3%), 14 in
stage III (29.2%) and 1 in GOLD stage IV (2.1%). A slight but
statistically significant decline in FEV1 was observed (ANOVA
for repeated measures po0.001; mean difference T1T9:
129.6722.8 (SEM)ml (95%CI: 64–195ml; pair-wise compar-
ison with Bonferroni’s method po0.001), that is a 18722ml
year decline (95%CI: 24.4 to 11.6), that is about the same
than in normal population.
MIP did not change over time whereas MEP remained
stable at the first three observations (T1–T3) and then
resulted to be significantly (ANOVA po0.001) reduced over
the last two observations (mean difference T1–T9: 8.2%,
95%CI: 2.2–14.2%; p ¼ 0.002), as well as DLCO (% predicted).
(ANOVA po0.001; mean difference T1–T9: 7.5%; 95%CI:
3.1–11.9%; po0.001).Exercise tolerance
As shown in Fig. 1 (upper-left and upper-right panels),
exercise tolerance assessed at admission to each PRP did not
change throughout the study period, independent of the
method of evaluation, whether the 6MWD or incremental
cyclo-ergometry.Subjective sensations
Table 2 shows the time course of dyspnoea at admission to
each PRP as assessed by the BDI and MRC. Despite some
fluctuations of perceived dyspnoea over the study period
(Friedmans’s test p ¼ 0.05 and 0.009 for BDI and MRC,
respectively), no statistically significant difference was
observed in either scores at T9 when compared to T1
(Wilcoxon signed ranks tests T1–T9: p ¼ 0.31 and 0.337 for
BDI and MRC, respectively) (Fig. 1, lower-left panel).Health-related quality of life
Table 3 shows the time course of the HRQL assessed at
admission of each PRP by means of the SGRQ, as total score
and as separate domains of ‘‘symptoms’’, ‘‘activity’’ and
‘‘impact’’. Total score (Fig. 1, lower-right panel) signifi-
cantly improved throughout the study period (Friedman’s
test po0.001); this improvement was equally distributed
among the three domains of ‘‘symptoms’’ (Friedman’s test
p ¼ 0.005), ‘‘activity’’ (Friedman’s test p ¼ 0.005) and
‘‘impact’’ (Friedman’s test p ¼ 0.004). The greatest im-
provement in total score was observed between T1 and T3,
whereas later on HRQL remained stable (Table 3).
As also shown in Table 3, BODE index significantly
worsened by 29% from T1 to T9 (1.6771.42–2.1571.66;
Friedman’s test p ¼ 0.004), being this change mainly
attributable to the slight worsening in FEV1 (from 1.0271
to 1.3171.03; Friedman’s test p ¼ 0.002).Changes induced by PRPs
Exercise tolerance
As expected7 and as shown in Fig. 1, each PRP was able to
elicit a statistically significant improvement in 6MWD which,
however, was less than reported as the smallest difference
associated with a noticeable clinical difference for COPD
patients23 (Fig. 1, upper-left panel). Peak workload attained
at exercise test improved significantly after PRP1 through
PRP4, whereas it remained unchanged after PRP5 (Fig. 1,
upper-right panel). The benefit in exercise tolerance gained
after each PRP was lost at the following PRP admission;
moreover, the extent of improvement in exercise capacity
reduced significantly over time (ANOVA p ¼ 0.009 and
po 0.001 for 6MWD and peak workload, respectively). In
particular, the extent of improvement in peak workload was
greater (p ¼ 0.001) after PRP1 and PRP3 when compared to
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Figure 1 Time course of exercise tolerance as assessed by 6MWD (upper-left panel) and cycloergometry peak workload (upper-right
panel), dyspnoea as assessed by MRC scale score (lower-left panel) and HRQL (by SGRQ) lower-right panel) in the 48 patients who
completed five consecutive PRPs. Lines and marks represent mean values at the different time points of the observational period.
Vertical bars represent SD. *po0.001 after versus before each PRP. ypo0.001 versus T0.
Seven-year time course in COPD patients undergoing pulmonary rehabilitation programs 1965after PRP5. When considering the whole study period, the
total number of improvers in 6MWD significantly decreased
over time being 16 out of 48 at T2 (33%), 15 at T4 (31%), 16
at T6 (33%), 6 at T8 (12.5%): (w2 p ¼ 0.01 versus T2) and 7 at
T10 (14.6%), (w2 p ¼ 0.03 versus T2).
Dyspnoea
All PRPs, but not PRP5, were followed by a significant
(Wilcoxon’s test po0.001) improvement of perceived
dyspnoea, as assessed either by TDI or MRC score (Fig. 1,
lower-left panel). Time course of changes induced by each
PRP was different between the two scores (Table 2). The
extent of dyspnoea relief, as assessed by TDI, induced by
each PRP significantly decreased over time (Friedman’s test
p ¼ 0.009); in contrast, change in MRC was greatest after
PRP1 and remained fairly stable after PRP2, PRP3 and PRP4,
finally being least after PRP5 (Friedman’s test p ¼ 0.01)
(Table 2).
Health-related quality of life
SGRQ total score improved significantly after each PRP
(Wilcoxon’s test po 0.001 for all after PRP evaluations)
(Fig. 1, lower-right panel), but to a greater extent following
PRP1 (Table 3) than after the other post-PRP evaluations.Unlike exercise tolerance (6MWD), frequency of patients
attaining a clinically significant change in SGRQ did not
change across the study period, being 6 out of 48 (12.5%), 4
(8.3%), 6 (12.5%), 6 (12.5%) and 7 (14.6%) at T2, T4, T6, T8
and T10, respectively.
BODE total score significantly improved after each PRP
(from 1.6771.42 to 1.2771.14 after PRP1, signed ranks
po0.001; from 1.5271.32 to 1.2171.22 after PRP2
po0.001; from 1.7571.31 to 1.4071.2 after PRP3
po0.001; from 1.9871.59 to 1.5871.47 after PRP4
po0.001 and from 2.1571.66 to 1.9871.64 after PRP5
p ¼ 0.011). This change was due to improvement in MRC
score (po0.0001 after PRP1, PRP2, PRP3 and PRP4; p ¼ 0.06
after PRP5).Exacerbations and hospitalisations
Frequency and distribution of exacerbations in the 1-year
period prior to and in the years of the observational period
are shown in Fig. 2. When compared to the year before the
first PRP (2.5470.9), mean number of exacerbations/
patient observed in the following years significantly
decreased (1.0270.86 po0.001, 0.8170.73 po0.001,
0.7970.77 po0.001, 0.9670.072 po0.001 after PRP1,
PRP2, PRP3, PRP4, respectively). Also the number of
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Table 2 Time course of dyspnoea as assessed by BDI/TDI and MRC and changes induced by each PRP.
PRP1 PRP2 PRP3 PRP4 PRP5
T1 Mean
diff.
T2T1
T3 Mean
diff.
T4T3
T5 Mean
diff.
T6T5
T7 Mean
diff.
T8T7
T9 Mean diff.
T10T9
p among
pre-rehab
times
p among
post-
rehab
changes
BDI 6.871.3 7.371.5 6.671.3 6.771.3 6.571.4 0.05y
TDI 5.872.2 4.872 4.271.8 3.471.7 2.871.7 0.009y
MRC 1.570.6 0.670.5 1.470.6 0.370.5 1.670.6 0.470.5 1.870.6 0.470.5 1.670.7 0.270.4z 0.009y 0.01y
TDI refers to post–pre-PRP mean difference.
yFriedman’s Test
Wilcoxon signed ranked test p ¼ 0.001 versus change T2T1, T4T3, and T6T5, p ¼ 0.044 versus change T8T7.
zWilcoxon signed ranked test p ¼ 0.001 versus change T2T1, p ¼ 0.033 versus change T6T5 and p ¼ 0.012 versus change T8T7.
Table 3 Time course of St. George Respiratory Questionnaire score and BODE index at pre-rehabilitation times and as post-rehabilitation changes
PRP1 PRP2 PRP3 PRP4 PRP5
T1 Mean diff.
T2T1
T3 Mean diff.
T4T3
T5 Mean diff.
T6T5
T7 Mean diff.
T8T7
T9 Mean diff.
T10T9
p among pre-rehab
times
p among post-rehab
changes
SGRQ, total
score
45.07713.59 9.33710.27y 37.36714.88 4.8277.66 36.22712.67 4.3176.51 35.07714.7 4.6478.77 35.40714.59 5.2479.09 o0.001 0.067
Symptoms, % 52.16718.78 2.96713.89 47.13718.61 4.84710.15 42.13720.06 4.53712.94 41.16720.36 5.73716.41 40.84722.15 9.18717.26 0.005 0.198
Activity, % 58.62714.58 10.44712.84 50.67718.20 11.51713.35 50.42714.92 8.31711.02 49.31718.35 2.1178.61 49.82715.91 3.13711.82 0.005 o0.001
Impact, % 34.38715.75 4.91711.12 26.93715.85 4.2478.51 26.56714.23 4.7179.02 24.84715.69 4.67710.25 25.58717.09 4.5878.53 0.004 0.023
BODE total
score
1.6771.42 0.470.57 1.5271.32 0.3170.51 1.7571.31 0.3570.48 1.9871.6 0.470.54 2.1571.66 0.1770.43 0.004 0.105
BMI score 0.170.31 070 0.0870.28 070 0.0870.280 070 0.0870.280 070 0.0870.280 070 0.92 0.98
FEV1 score 1.0271 070 0.9670.99 070 1.0870.96 070 1.171 070 1.3171.03 070 0.002 0.99
MRC score 0.570.65 0.3570.53 0.4870.54 0.3170.51 0.5870.54 0.3570.48 0.7570.6 0.3770.49 0.5870.65 0.170.37 0.01 0.26
6MWT score 0.0470.2 0.0470.2 070 070 070 070 0.0670.24 0.2170.14 0.1770.52 0.0670.24 0.011 0.82
Friedman’s test.
yWilcoxon signed ranked test p ¼ 0.02 versus change T4T3, p ¼ 0.002 versus change T6T5, p ¼ 0.008 versus change T8T7 and p ¼ 0.026 versus change T10T9.
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Figure 2 Frequency distribution of hospitalisations (solid bars) and exacerbations (white bars) during 1 year prior to and after PRP1,
PRP2, PRP3 and PRP4.
Seven-year time course in COPD patients undergoing pulmonary rehabilitation programs 1967patients free from exacerbations increased significantly (w2
po0.001) after each PRP when compared to the year before
the observational period (1 patient), being 14, 17, 19 and 13
patients after PRP1, PRP2, PRP3 and PRP4, respectively.
Frequency and distribution of hospitalisations in the 1-
year period prior to and in the years of the observational
period are also shown in Fig. 2. The mean number of
hospitalisations per patient in the year before the observa-
tional period was 0.6870.09, which was significantly greaterthan after PRP1 (0.0870.04 po0.001), PRP2 (0.0870.05
po0.001), PRP3 (0.0270.02 po0.001) and PRP4 (0.1570.05
po0.001). Moreover, when compared to the 1-year prior to
observational period (20/48 patients), the number of
patients free from hospitalisation was greater after PRP1
(44/48 w2 po0.001), PRP2 (45/48 w2 po0.0001), PRP3 (47/48
w2 po0.001) and PRP4 (40/48 w2 po0.001) (Fig. 2).
Finally, no correlation was found between decline in lung
function and any of the outcome measures (before and after
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K. Foglio et al.1968PRP) as well as with rate of hospitalisations and exacerba-
tions experienced by the patients throughout the study
period.
Discussion
There are few studies of the long-term time course of
outcome measures in COPD patients. This study shows that
along a period of 7 years, COPD patients undergoing
repeated PRPs do not show any significant worsening in
exercise tolerance, dyspnoea, and health related quality of
life. PRP appear progressively less effective in improving
such outcome measures.
Evidence-based support for pulmonary rehabilitation in
the management of COPD patients has grown tremendously
in the last decade, and this comprehensive intervention has
been unequivocally demonstrated to reduce dyspnoea,
increase exercise performance, and improve HRQL. Further-
more, an emerging literature is beginning to reveal its
effectiveness in reducing health care costs.4,5
Lung function
An interesting result of our study is the reduced rate of
decline in lung function as assessed by FEV1. In fact our
patients showed a mean 18ml year decline in FEV1, a value,
lower than reported in some studies25 but not in others,26
that is about the same than in normal population. The
reason for this observation is not clear. No short-term
improvement in lung function is reported after PRP.4 We can
speculate that, smoking cessation,2,27 programmed visits,
and related optimisation of medical therapy might have
contributed to this result. The possibility that these patients
who attended five consecutive PRPs were just those whose
lung function loss was the least, cannot be definitely ruled
out. That would also give a plausible explanation for the
small number of deaths observed throughout the study
period, although an indirect relationship between mortality
and exercise capacity has been suggested.28,29 Nevertheless
another explanation is possible: it has been recently shown
that regular physical activity may reduce lung function
decline and risk of developing COPD among active smo-
kers.30
Another possible explanation for this observation may be
related to the reduction in number of exacerbations in the
years following the PRP which confirms the results of other
studies4,7,28 (Fig. 2), although no significant correlation was
found in this study. It has been reported that acute
exacerbations of COPD may be important in decline of lung
function.31,32 Recently, Donaldson et al.33 have shown that
moderate to severe COPD patients who suffered from
frequent exacerbations experienced a significantly greater
year decline in FEV1 of 40ml than patients who had
infrequent exacerbations in whom the year FEV1 decline
was 32ml. Seemungal et al.34 demonstrated that recovery
from a decline in lung function after COPD exacerbation may
be very slow: at 35th day, the peak expiratory flow rate in
75% of cases had returned to baseline level, but at 91st day,
the PEF in 7% of cases had not returned yet to baseline and
in 3% of cases a further exacerbation had occurred before
recovery was completed. Therefore, it may be possible thatthe observed low FEV1 decline rate is related to reduction in
exacerbations observed in our patients.
An original result of our study is that MIP did not change
over time whereas MEP remained stable at the first three
observations and then resulted to be significantly reduced
over the last two observations. The long-term course of
respiratory muscle function of COPD patients has not been
reported before. The lack of changes in MIP is not surprising
as our PRP did not include any specific respiratory muscle
training.35
Exercise tolerance
Exercise tolerance did not change throughout the study
period, independent of the evaluation whether the 6MWD or
incremental cycloergometry. We used incremental cycloer-
gometry and 6MWD as indexes of exercise capacity. As
reported previously these two methods to assess exercise
capacity explore aspects somehow different. However,
strong relationships between the two methods are re-
ported.36 It has been shown that in moderate-to-very severe
COPD patients (mean FEV1 ¼ 37% predicted) exercise capa-
city deteriorated over time at a rate defined as no less rapid
than decline in airflow limitation.37 The lack of decline in
exercise capacity observed in our patients is important. It
has been shown that 6MWD as well as peak VO2 predict
mortality.38,39
Dyspnoea
In agreement with stability in exercise capacity, our patients
did not suffer from progressive worsening in subjective
sensations of dyspnoea. This is an important issue. It has
been suggested that the categorisation of patients with
COPD on the basis of the level of dyspnoea was more
discriminating than staging of disease severity on the basis
of airway obstruction with respect to the 5-year survival.40
Health-related quality of life
SGRQ total score significantly improved throughout the
study period. The greatest improvement in total score being
observed between T1 and T3, whereas later on HRQL
remained stable. Other authors have found evidence of a
measurable and progressive deterioration in all the compo-
nents of the SGRQ of a population of COPD patients. The
rate of deterioration was correlated with FEV1 decline.
41 At
difference with exercise capacity, in our study HRQL
improved in the first year and thereafter remained stable.
In other words, at least in this population of COPD patients
undergoing several PRPs there is a dissociation between
exercise capacity and HRQL. This observation has been
reported also in other studies6,7,42 and probably reflects the
comprehensive nature of the PRP and the fact that HRQL
depends on more than just exercise ability. Although it has
been shown that hospitalisations and exacerbations are
important determinants of health status in COPD pa-
tients,43,44 whether the maintenance of good HRQL ob-
served in patients of our study is related to reduced
hospitalisations and exacerbations is still speculative.
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this change mainly attributable to ‘‘normal-like’’ decline in
FEV1. It has been shown that the BODE index
22 captures the
beneficial effects induced by pulmonary rehabilitation in
COPD patients,29 suggesting that the post-rehabilitation
response in BODE may play a role in their long-term survival.
In that study,29 the BODE improved by 19% after a PRP and
returned to baseline after 2 years. The BODE worsened in
patients not submitted to PRP by 4% at 12 months and 18% at
2 years. As a unique result, our study is the first to describe
the long-time course of this index in these patients, the
overall worsening at 7 years being 29%. Being the observed
worsening of BODE index mainly related to the slight decline
in FEV1, we cannot speculate on its clinical meaning in our
patients, given that a ‘‘physiological’’ worsening in BODE
index in normals is not reported.
Changes induced by PRPs
As expected,4,7 each PRP was able to elicit significant
improvement in 6MWD and in peak cycloergometry work-
load. Nonetheless, the benefit in exercise tolerance gained
after each program was lost at the following PRP admission;
moreover, the extent of improvement generated by each
PRP of both 6MWD and peak work rate reduced significantly
over time. Each PRP was followed by an improvement in
perceived dyspnoea. SGRQ total score improved significantly
after each PRP but to a greater extent following the first PRP
than after the other post-PRP evaluations. In summary, PRP
appear progressively less effective in improving outcome
measures.
Limitations of the study
The lack of a control group not performing PRP might be
criticised. Nevertheless, given the demonstrated effective-
ness of pulmonary rehabilitation,4 it would be unethical not
to perform it in a control group.
In conclusion, this study shows that along a period of 7
years COPD patients undergoing repeated PRPs do not show
any significant worsening in exercise tolerance, dyspnoea,
and health-related quality of life. PRP appear progressively
less effective in improving such outcome measures.
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